TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10867087

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (specifics not provided)
Number of subjects: 1830

Group type: EXPERIMENTAL
Intervention: In-hospital revascularization (specifics not provided)
Number of subjects: 1830

Group type: EXPERIMENTAL
Intervention: Calcium antagonists (specifics not provided)
Number of subjects: 1830
Study: 9354489

Group type: EXPERIMENTAL
Intervention: Isokinetic trunk rotatory muscle performance
Number of subjects: 65

Group type: COMPARATOR
Intervention: Healthy controls (80 subjects, 38 females)
Number of subjects: 65
Study: 8416053

Group type: EXPERIMENTAL
Intervention: 0.2 mg of Protirelin (synthetic TRH) intravenously
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 2939126

Group type: EXPERIMENTAL
Intervention: 200 micrograms folic acid
Number of subjects: 75

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Increased plasma folate to 13 ng/ml or above
Number of subjects: 75
Study: 30464411

Group type: EXPERIMENTAL
Intervention: SB5 administered via autoinjector (AI)
Number of subjects: 190

Group type: COMPARATOR
Intervention: SB5 administered via prefilled syringe (PFS)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Both groups (SB5 AI and SB5 PFS)
Number of subjects: 190
Study: 27194048

Group type: COMPARATOR
Intervention: Single goal intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multiple goal intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (received information about community health resources)
Number of subjects: 0
Study: 25436296

Group type: EXPERIMENTAL
Intervention: 0.1 mg ramosetron 1 hour before ingestion of a test meal (200 kcal per 200 mL, containing 100 mg 13C acetate)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Test meal alone
Number of subjects: 10
Study: 21953277

Group type: EXPERIMENTAL
Intervention: BMI-associated gene variant QPCTL rs2287019 C allele
Number of subjects: 6039

Group type: EXPERIMENTAL
Intervention: BMI-associated gene variant LRP1B rs2890652 C allele
Number of subjects: 6039

Group type: EXPERIMENTAL
Intervention: WHR-associated gene variant LYPLAL1/SLC30A10 rs4846567 G allele
Number of subjects: 6039

Group type: EXPERIMENTAL
Intervention: WHR-associated gene variant VEGFA rs6905288 A allele
Number of subjects: 6039
Study: 19495810

Group type: EXPERIMENTAL
Intervention: Aqua lymphatic therapy (ALT) for 3 months in addition to self-management therapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Self-management treatment
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Aqua lymphatic therapy (ALT)
Number of subjects: 48
Study: 17481662

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (100 mouse units of Dysport)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 15754234

Group type: EXPERIMENTAL
Intervention: Dynamic Hip Screw (DHS)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Proximal Femur Nail (PFN)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: ASA Classification
Number of subjects: 112
Study: 12086383

Group type: EXPERIMENTAL
Intervention: 4 F catheter
Number of subjects: 500

Group type: COMPARATOR
Intervention: 6 F catheter
Number of subjects: 500
Study: 9459339

Group type: EXPERIMENTAL
Intervention: 5 mg enalaprilat intravenously prior to thrombolysis
Number of subjects: 23
Study: 7629560

Group type: EXPERIMENTAL
Intervention: Ceftazidime (1 g, intramuscularly administered)
Number of subjects: 25
Study: 2535067

Group type: EXPERIMENTAL
Intervention: mesoglycan (72 mg/day orally)
Number of subjects: 90

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: mesoglycan
Number of subjects: 90
Study: 31123606

Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26755506

Group type: EXPERIMENTAL
Intervention: New sedation policy (sequential administration of melatonin, hydroxyzine, and chloral hydrate)
Number of subjects: 803

Group type: COMPARATOR
Intervention: Old sedation policy (sole administration of chloral hydrate)
Number of subjects: 803

Group type: EXPERIMENTAL
Intervention: New sedation policy
Number of subjects: 803
Study: 25913070

Group type: EXPERIMENTAL
Intervention: Nimorazole (NIM) administered at a dose of 1.2g/m2, 90 minutes before the first daily radiotherapy (RT) fraction.
Number of subjects: 104

Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone.
Number of subjects: 104
Study: 23993464

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 22004601

Group type: EXPERIMENTAL
Intervention: Full drug-eluting stent (DES) coverage (n = 90)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Spot drug-eluting stent (DES) coverage (n = 89)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Spot DES
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Spot DES (after controlling for confounding factors)
Number of subjects: 179
Study: 18238861

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carotid endarterectomy
Number of subjects: 0
Study: 16608954

Group type: EXPERIMENTAL
Intervention: docetaxel, 35 mg/m(2) IV infusion (D(35)) on days 1, 8, and 15 every 4 weeks
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: docetaxel, 40 mg/m(2) IV (D(40)) on days 1 and 8 every 3 weeks
Number of subjects: 161

Group type: COMPARATOR
Intervention: docetaxel, 75 mg/m(2) IV (D(75)) on day 1 every 3 weeks
Number of subjects: 161
Study: 14511275

Group type: EXPERIMENTAL
Intervention: 40 mg dose of eletriptan
Number of subjects: 113
Study: 10811333

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum (DSM 9843) in a rose-hip drink (400 ml per day, 5 x 10(7) cfu/ml)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Plain rose-hip drink (control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum (DSM 9843) in a rose-hip drink
Number of subjects: 60
Study: 8644026

Group type: EXPERIMENTAL
Intervention: Neoton infusions (30 g/day for 3 days)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Emoxipin injected intramuscularly (3 mg/kg for 20 days)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Emoxipin injected intravenously (10 mg/kg)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (100 patients)
Number of subjects: 55
Study: 1352245

Group type: EXPERIMENTAL
Intervention: xamoterol (200 mg b.i.d. for 7 days)
Number of subjects: 10
Study: 6432857

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 1

Group type: COMPARATOR
Intervention: Phenytoin
Number of subjects: 1

Group type: COMPARATOR
Intervention: Valproic acid
Number of subjects: 1
Study: 30696041

Group type: EXPERIMENTAL
Intervention: MicroLactin® (ML)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 58
Study: 30368330

Group type: EXPERIMENTAL
Intervention: WM training group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 26152242

Group type: EXPERIMENTAL
Intervention: Hand-held navigation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (no navigation)
Number of subjects: 80
Study: 24467942

Group type: EXPERIMENTAL
Intervention: Reboxetine (4 mg single dose)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 21770829

Group type: EXPERIMENTAL
Intervention: Melatonin treatment (Group A)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control (no melatonin treatment, Group B)
Number of subjects: 85
Study: 21147712

Group type: EXPERIMENTAL
Intervention: 60 mg iron as ferrous sulfate
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: 60 mg iron and 0.4 mg folic acid
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: 60 mg iron, 2.0 mg retinol and 0.4 mg folic acid
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study: 16844502

Group type: EXPERIMENTAL
Intervention: Retinyl N‐formyl aspartamate applied twice daily on the left half of the face
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo applied on the right half of the face
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Retinyl N‐formyl aspartamate
Number of subjects: 29
Study: 14708457

Group type: EXPERIMENTAL
Intervention: Clinidipine (10 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Quinapril (10 mg)
Number of subjects: 60
Study: 11185412

Group type: EXPERIMENTAL
Intervention: Gemifloxacin 320 mg in fasted state
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Gemifloxacin 320 mg after a high fat meal
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Gemifloxacin 640 mg in fasted state
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Gemifloxacin 640 mg after a high fat meal
Number of subjects: 21
Study: 9183304

Group type: EXPERIMENTAL
Intervention: Low-fat, low-cholesterol diet during the dietary intervention
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Switchback to original diet
Number of subjects: 86
Study: 1562720

Group type: EXPERIMENTAL
Intervention: Consolidation therapy (6 days of high-dose cytarabine plus 3 days of amsacrine)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Maintenance therapy (2 years of continuous outpatient therapy with cytarabine and 6-thioguanine)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation (alloBMT)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Consolidation therapy
Number of subjects: 224

Group type: COMPARATOR
Intervention: Maintenance therapy
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: AlloBMT
Number of subjects: 224
Study: 4011145

Group type: EXPERIMENTAL
Intervention: Cyclopentolate 0.5% eyedrops
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cyclopentolate 0.25% eyedrops
Number of subjects: 20
Study: 31601494

Group type: EXPERIMENTAL
Intervention: Ketorolac (15-mg IV every 6 hours)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Acetaminophen (1-g IV every 6 hours)
Number of subjects: 100
Study: 29023185

Group type: EXPERIMENTAL
Intervention: Low-Intensity Laser Therapy (LLLT) - InGaAlP, λ 660 nm, energy density 6 J/cm2, applied daily from the first to the fourth postoperative day.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo Group (PG)
Number of subjects: 40
Study: 26660143

Group type: EXPERIMENTAL
Intervention: Secukinumab (single regimen, baseline only)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Secukinumab (monthly regimen, baseline, weeks 4, 8)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Secukinumab (early regimen, baseline, weeks 1, 2, 4)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study: 24512609

Group type: EXPERIMENTAL
Intervention: Distractor-filtering during encoding
Number of subjects: 3268

Group type: EXPERIMENTAL
Intervention: Distractor-filtering during maintenance
Number of subjects: 3268

Group type: COMPARATOR
Intervention: No distractors
Number of subjects: 3268
Study: 23231928

Group type: EXPERIMENTAL
Intervention: Physiotherapy plus nurse-delivered telephone coaching
Number of subjects: 168

Group type: COMPARATOR
Intervention: Physiotherapy only
Number of subjects: 168
Study: 20334980

Group type: EXPERIMENTAL
Intervention: Social exclusion (Cyberball condition)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Inclusion (Cyberball condition)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Technical default (Cyberball condition)
Number of subjects: 89
Study: 17029788

Group type: EXPERIMENTAL
Intervention: Exercise and advice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Advice alone
Number of subjects: 0
Study: 16585986

Group type: EXPERIMENTAL
Intervention: 0.3% Tacrolimus gel
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: 0.5% Tacrolimus cream
Number of subjects: 124

Group type: COMPARATOR
Intervention: Calcipotriol ointment
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Tacrolimus gel and cream
Number of subjects: 124
Study: 14644852

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 7

Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Paracetamol recommended
Number of subjects: 7
Study: 10991830

Group type: COMPARATOR
Intervention: Ciprofloxacin 250 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Gatifloxacin 400 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Grepafloxacin 600 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Trovafloxacin 200 mg
Number of subjects: 12
Study: 8834029

Group type: EXPERIMENTAL
Intervention: Octreotide (100-micrograms/h infusion after a 100-micrograms bolus)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 1410154

Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum (first dose)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum (second and third doses)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo gum condition
Number of subjects: 13
Study: 3907259

Group type: EXPERIMENTAL
Intervention: Single instillation of 0.85% cyclopentolate + 1.5% phenylephrine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Atropine eye drops applied twice a day for 3.5 days
Number of subjects: 40
Study: 30219459

Group type: EXPERIMENTAL
Intervention: Sunlight exposure with vitamin D supplementation (20,000 IU weekly)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sunlight exposure alone
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both groups (Sunlight exposure and Sunlight exposure with vitamin D supplementation)
Number of subjects: 52
Study: 27569841

Group type: EXPERIMENTAL
Intervention: simvastatin/ezetimibe
Number of subjects: 1684

Group type: COMPARATOR
Intervention: simvastatin/placebo
Number of subjects: 1684
Study: 24731384

Group type: COMPARATOR
Intervention: Single-bundle (SB) technique
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Double-bundle (DB) technique
Number of subjects: 50
Study: 22497677

Group type: EXPERIMENTAL
Intervention: bisoprolol 10 mg/day
Number of subjects: 27

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 27
Study: 19755497

Group type: EXPERIMENTAL
Intervention: Bike Smart program (eHealth software program)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control condition (a video on childhood safety)
Number of subjects: 206
Study: 18325025

Group type: EXPERIMENTAL
Intervention: Citicoline (Cebrolux-Tubilux, Italy, 1600 mg/diem for 60 days)
Number of subjects: 26

Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 26
Study: 16091759

Group type: EXPERIMENTAL
Intervention: docetaxel
Number of subjects: 283

Group type: COMPARATOR
Intervention: sequential methotrexate‐fluorouracil (MF)
Number of subjects: 283
Study: 12360462

Group type: EXPERIMENTAL
Intervention: Medical therapy (beta-blockers and nitrates)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Endoscopic banding
Number of subjects: 102
Study: 10858764

Group type: EXPERIMENTAL
Intervention: Examiners' training programme with pictorial handout and two one-hour diagnostic seminars
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control group (not specified what intervention was used)
Number of subjects: 5
Study: 8708716

Group type: EXPERIMENTAL
Intervention: Low-dose methotrexate (40 mg/m2) added to high-dose infusional 5-FU (60 mg/kg over 48 hours) given weekly for 4 weeks and thereafter every 2 and 3 weeks.
Number of subjects: 310

Group type: COMPARATOR
Intervention: High-dose infusional 5-FU without low-dose methotrexate.
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: High-dose infusional 5-FU with low-dose methotrexate.
Number of subjects: 310
Study: 1894476

Group type: EXPERIMENTAL
Intervention: Peripheral color contrast test for glaucoma patients
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Peripheral color contrast test for ocular hypertensive patients
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: High-risk ocular hypertensive patients
Number of subjects: 45
Study: 6756933

Group type: EXPERIMENTAL
Intervention: muzolimine (35 +/- 2 mg/day for six weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 31566689

Group type: EXPERIMENTAL
Intervention: Enhanced tablet-based book
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Basic tablet-based book
Number of subjects: 37

Group type: COMPARATOR
Intervention: Print book
Number of subjects: 37
Study: 28459925

Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) intervention
Number of subjects: 300

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 300
Study: 25321146

Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG) 50 mg twice daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 23195283

Group type: EXPERIMENTAL
Intervention: Mirabegron 50mg
Number of subjects: 2444

Group type: EXPERIMENTAL
Intervention: Mirabegron 100mg
Number of subjects: 2444

Group type: COMPARATOR
Intervention: Tolterodine ER 4 mg
Number of subjects: 2444
Study: 21651819

Group type: EXPERIMENTAL
Intervention: Post-fracture clinic intervention
Number of subjects: 130

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 130
Study: 18837701

Group type: EXPERIMENTAL
Intervention: Synthetic ellagic acid
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Plant extract containing natural ellagic acid
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Arbutin
Number of subjects: 30
Study: 17139639

Group type: EXPERIMENTAL
Intervention: Behavioral graded activity (BGA)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care (UC; exercise therapy and advice)
Number of subjects: 200
Study: 12629448

Group type: EXPERIMENTAL
Intervention: Functional insulin therapy with short-acting insulin analog
Number of subjects: 110
Study: 10729293

Group type: EXPERIMENTAL
Intervention: Vitrectomy with complete posterior cortical vitreous peeling
Number of subjects: 102

Group type: COMPARATOR
Intervention: Vitrectomy with peeling of the posterior hyaloid in the area of the macula without complete posterior vitreous detachment
Number of subjects: 102
Study: 8940672

Group type: EXPERIMENTAL
Intervention: Podophyllotoxin cream 0.15%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Podophyllotoxin cream 0.3%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Podophyllotoxin solution 0.5%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Podophyllotoxin cream 0.15% (female)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Podophyllotoxin cream 0.3% (female)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Podophyllotoxin solution 0.5% (female)
Number of subjects: 0
Study: 1527313

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray 200 micrograms once a day
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aqueous nasal spray 168 micrograms twice a day
Number of subjects: 313

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study: 3873880

Group type: EXPERIMENTAL
Intervention: Pancuronium (n = 12)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Metocurine (n = 9)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Metocurine-pancuronium combination (4:1 ratio by weight) (n = 12)
Number of subjects: 33
Study: 31144825

Group type: EXPERIMENTAL
Intervention: Brief motivational interventions (BMI) consisting of a single 45- to 60-min session
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: More experienced therapists conducting BMIs
Number of subjects: 228
Study: 29997032

Group type: EXPERIMENTAL
Intervention: High-velocity, low-amplitude spinal manipulation (HVLA SM)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Side-posture positioning
Number of subjects: 111

Group type: COMPARATOR
Intervention: Joint preloading with no thrust
Number of subjects: 111
Study: 27378733

Group type: EXPERIMENTAL
Intervention: Home- and community-based exercise program (12 weeks, with once-weekly telephone or e-mail support)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 20
Study: 25637265

Group type: EXPERIMENTAL
Intervention: Buspirone (a partial 5-HT1A receptor agonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 0
Study: 23898485

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 28
Study: 21138709

Group type: COMPARATOR
Intervention: 0.0 g/kg alcohol dose
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: 0.125 g/kg alcohol dose
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: 0.25 g/kg alcohol dose
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: 0.5 g/kg alcohol dose
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: 0.75 g/kg alcohol dose
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: 1.0 g/kg alcohol dose
Number of subjects: 187
Study: 18324570

Group type: EXPERIMENTAL
Intervention: Negative Affect (NA)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Somatic Features (SF)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Low Positive Affect/Anhedonia (PA)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Interpersonal Disturbance (IP)
Number of subjects: 157
Study: 16979410

Group type: EXPERIMENTAL
Intervention: Active group (n = 15) instructed to walk at least 10000 steps per day 5 or more days per week for 6 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Active group (n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (n = 15)
Number of subjects: 30
Study: 14656780

Group type: EXPERIMENTAL
Intervention: iv ondansetron 4 mg
Number of subjects: 70
Study: 11477055

Group type: EXPERIMENTAL
Intervention: Leaflets (simple summary leaflet or FPA leaflet)
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Advice
Number of subjects: 636

Group type: COMPARATOR
Intervention: Neither (control group)
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Leaflets with past emergency contraception use
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Leaflets without past emergency contraception use
Number of subjects: 636
Study: 10195004

Group type: EXPERIMENTAL
Intervention: Iodixanol (600 mgI kg‐1 bw, 320 mgI ml‐1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Iopromide (600 mgI kg‐1 bw, 300 mgI ml‐1)
Number of subjects: 100